SuperworthKewaunee Scientific free cash flow KEQU
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 31, 2026
- $10.9M
- Latest quarter, Q1 FY27
- $1.2M
- −76% on a year earlier
- Fiscal year 2026
- $14.7M
- +16% on the year before
Kewaunee Scientific's free cash flow was $10.9M over the twelve months to Jul 31, 2026, down 42% on a year earlier.
In its latest quarter, Q1 FY27, it was $1.2M, down 76% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2026 | $14.7M | +16% |
| FY2025 | $12.6M | −17% |
| FY2024 | $15.2M | n/a |
| FY2023 | −$7.9M | n/a |
| FY2022 | −$9.8M | n/a |
| FY2021 | −$1.5M | −188% |
| FY2020 | $1.7M | n/a |
| FY2019 | −$1.7M | n/a |
| FY2018 | −$212K | −102% |
| FY2017 | $9.1M | +78% |
| FY2016 | $5.1M | n/a |
| FY2015 | −$277K | −105% |
| FY2014 | $6M | +325% |
| FY2013 | $1.4M | −74% |
| FY2012 | $5.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $1.2M | −76% | $10.9M | |
| Q4 FY26 | $4.5M | −49% | $14.7M | |
| Q3 FY26 | $11M | n/a | $19.1M | |
| Q2 FY26 | −$5.8M | −175% | $5.1M | |
| Q1 FY26 | $5M | n/a | $18.7M | |
| Q4 FY25 | $8.9M | +5256% | $12.6M | |
| Q3 FY25 | −$3M | −133% | $3.9M | |
| Q2 FY25 | $7.8M | n/a | $15.9M | |
| Q1 FY25 | −$1.1M | −116% | $7.6M | |
| Q4 FY24 | $166K | n/a | $15.2M | |
| Q3 FY24 | $9M | n/a | $12.2M | |
| Q2 FY24 | −$518K | n/a | −$433K |
Against its peers
Companies in Medical - Instruments & Supplies nearest Kewaunee Scientific's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| KEQUKewaunee Scientific | 11.5% |
| APTAlpha Pro Tech | 10.3% |
| PDEXPro DEX | 3.4% |
| NEPHNephros | n/m |
| UTMDUtah Medical Products | 4.8% |
| INFUInfuSystem | 8.3% |
| EMBCEmbecta | n/m |
| TCMDTactile Systems Technology | 5.0% |
| MDXGMimedx | n/m |
| MOVMovado | 10.2% |
| Peer median | 6.6% |
Where Kewaunee Scientific ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Kewaunee Scientific
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.